Skip to main content

Table 2 Clinical characteristics of patients enrolled in the study at T0 and T12

From: Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis

 

HV

ERA

 

n

90

90

 

Female

72

72

 

Age—mean (range)

34.4 (19–51)

34.1 (19–50)

 

RF+ %

–

66

 

Anti-CCP+ %

–

68

 

Treatment %

 

T0

T12

Corticoids

–

–

11

MTX

–

–

93

Biologics

–

–

24

Hydroxychloroquine

–

–

5

Clinical measures

 

Mean (range)_T0

Mean (range)_T12

DAS28-CRP

–

4.4 (7.3–1.21)

2.7 (5.3–1.2)

SDAI

–

23.3 (70.4–0)

9.5 (77–0.1)

CDAI

–

21 (65.2–0)

8.2 (30–0)

TJC

–

9 (33–0)

2.9 (19–0)

TJC28

–

6.7 (26–0)

2.3 (19–0)

SJC

–

6.3 (27–0)

1.3 (8–0)

SJC28

–

4.8 (26–0)

1.1 (7–0)

CRP mg/dL

–

2.3 (26–0.09)

0.6 (10–0.02)

HAQ

–

1 (2.4–0)

0.7 (2.8–0)

VAS med

–

41.1 (89–10)

15.9 (70–0)

VAS pat

–

53.9 (100–0)

32.2 (90–0)

VAS pain

–

55 (100–0)

31 (90–0)

VAS fatigue

–

54.9 (100–0)

41.1 (96–0)

  1. HV healthy volunteers, ERA early rheumatoid arthritis, DAS28-CRP disease activity score 28 joints, SDA: Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, TJC28 28-Tender Joint Count, SJC28 28-Swollen Joint Count; HAQ Health Assessment Questionnaire, VAS Visual Analogue Scale
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us